Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Lymphoma, Large B-Cell, Diffuse × tofacitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Arthritis, Rheumatoid 2 Myasthenia Gravis 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Extranodal NK-T-Cell 1 Glioblastoma 1

Interventions

Rituximab 257 Cyclophosphamide 237 Etoposide 114 Prednisone 97 Vincristine 95 Peripheral Blood Stem Cell Transplantation 95 Doxorubicin 95 fludarabine phosphate 87 Filgrastim 80 Cytarabine 61 Lenalidomide 60 Mycophenolic Acid 59 Melphalan 59 Radiotherapy 57 Busulfan 52 Cyclosporine 50 Carmustine 49 Whole-Body Irradiation 48 Tacrolimus 46 Methotrexate 42 Antilymphocyte Serum 38 Gemcitabine 33 Ifosfamide 32 Carboplatin 32 fludarabine 31 Dexamethasone 30 polatuzumab vedotin 29 Granulocyte Colony-Stimulating Factor 29 CT-P10 28 Methylprednisolone 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05348213 2024-10-23

R-ICE+X

Ruijin Hospital

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡